Cellectis (ALCLS) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.016x

Based on the latest financial reports, Cellectis (ALCLS) has a cash flow conversion efficiency ratio of -0.016x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.57 Million ≈ $-1.84 Million USD) by net assets (€100.48 Million ≈ $117.47 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cellectis - Cash Flow Conversion Efficiency Trend (2005–2024)

This chart illustrates how Cellectis's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read ALCLS liabilities breakdown for a breakdown of total debt and financial obligations.

Cellectis Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Cellectis ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
I-Sheng Electric Wire & Cable Co Ltd TW:6115	-0.011x
Protara Therapeutics Inc NASDAQ:TARA	-0.086x
West Wits Mining Ltd AU:WWI	-0.096x
Omega Flex Inc NASDAQ:OFLX	0.032x
FVCBankcorp Inc NASDAQ:FVCB	0.030x
Idun Industrier AB Series B ST:IDUN-B	0.091x
Sonda S.A SN:SONDA	0.057x
Oak Valley Bancorp NASDAQ:OVLY	0.038x

Annual Cash Flow Conversion Efficiency for Cellectis (2005–2024)

The table below shows the annual cash flow conversion efficiency of Cellectis from 2005 to 2024. For the full company profile with market capitalisation and key ratios, see ALCLS market cap overview.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	€131.03 Million ≈ $153.19 Million	€22.99 Million ≈ $26.88 Million	0.175x	+160.05%
2023-12-31	€84.69 Million ≈ $99.02 Million	€-24.75 Million ≈ $-28.93 Million	-0.292x	+57.92%
2022-12-31	€125.94 Million ≈ $147.24 Million	€-87.44 Million ≈ $-102.23 Million	-0.694x	-57.03%
2021-12-31	€236.47 Million ≈ $276.46 Million	€-104.56 Million ≈ $-122.24 Million	-0.442x	-70.15%
2020-12-31	€308.85 Million ≈ $361.07 Million	€-80.26 Million ≈ $-93.83 Million	-0.260x	-33.61%
2019-12-31	€355.47 Million ≈ $415.58 Million	€-69.14 Million ≈ $-80.83 Million	-0.195x	-28.54%
2018-12-31	€450.27 Million ≈ $526.41 Million	€-68.14 Million ≈ $-79.66 Million	-0.151x	+17.32%
2017-12-31	€285.90 Million ≈ $334.25 Million	€-52.33 Million ≈ $-61.18 Million	-0.183x	-61.34%
2016-12-31	€274.05 Million ≈ $320.39 Million	€-31.09 Million ≈ $-36.34 Million	-0.113x	-1024.12%
2015-12-31	€288.22 Million ≈ $336.95 Million	€3.54 Million ≈ $4.14 Million	0.012x	-98.25%
2014-12-31	€72.39 Million ≈ $84.63 Million	€50.74 Million ≈ $59.32 Million	0.701x	+118.19%
2013-12-31	€6.65 Million ≈ $7.77 Million	€-25.63 Million ≈ $-29.96 Million	-3.854x	-1105.67%
2012-12-31	€81.69 Million ≈ $95.50 Million	€-26.11 Million ≈ $-30.53 Million	-0.320x	+10.29%
2011-12-31	€37.02 Million ≈ $43.28 Million	€-13.19 Million ≈ $-15.42 Million	-0.356x	+15.35%
2010-12-31	€50.13 Million ≈ $58.60 Million	€-21.10 Million ≈ $-24.67 Million	-0.421x	-337.25%
2009-12-31	€73.22 Million ≈ $85.60 Million	€-7.05 Million ≈ $-8.24 Million	-0.096x	-350.06%
2008-12-31	€46.21 Million ≈ $54.03 Million	€1.78 Million ≈ $2.08 Million	0.038x	+129.82%
2007-12-31	€43.54 Million ≈ $50.91 Million	€-5.62 Million ≈ $-6.57 Million	-0.129x	-400.76%
2005-12-31	€9.11 Million ≈ $10.65 Million	€391.00K ≈ $457.12K	0.043x	--

About Cellectis

PA:ALCLS France Biotechnology

Market Cap

$282.27 Million

€241.44 Million EUR

Market Cap Rank

#15207 Global

#222 in France

Share Price

€3.33

Change (1 day)

+3.29%

52-Week Range

€1.23 - €4.57

All Time High

€40.90